Genetics of C-Reactive Protein: New Possibilities and Complications

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 11, 2003, Pages 1956-1959

  Kluft, Comelis ^a   De Maat, Moniek P M ^a  

^a TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GUANINE NUCLEOTIDE; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; PYRIMIDINE NUCLEOTIDE; TOLL LIKE RECEPTOR 4;

CARDIOVASCULAR DISEASE; CORONARY ARTERY THROMBOSIS; DNA POLYMORPHISM; EDITORIAL; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC MARKER; GENETIC RISK; GENETIC VARIABILITY; HERITABILITY; HUMAN; INTRON; NUCLEOTIDE REPEAT; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN TARGETING; RISK ASSESSMENT;

C-REACTIVE PROTEIN; GENETIC MARKERS; HUMANS; INFLAMMATION; INTERLEUKIN-6; POLYMORPHISM, GENETIC; VARIATION (GENETICS);

EID: 0242576259     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000100113.47260.EB     Document Type: Editorial

References (31)

1. Pepys MB. Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805-1812.
2. Pankow JS, Folsom AR, Cushman M, Borecki IB, Hopkins PN. Eckfeldt JH, Tracy RP. Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. Atherosclerosis. 2001;154:681-689.
3. Vickers MA, Green FR, Terry C, Mayosi BM, Julier C, Lathrop M, Ratcliffe PJ, Watkins HC, Keavney B. Genotype at a promotor polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. Cardiovasc Res. 2002;53:1029-1034.
4. MacGregor AJ, Gallimore J, Spector TD, Pepys MB. Genetic factors determine baseline levels of C-reactive protein and serum amyloid A. Ann Rheum Dis. 1999:58:43. Abstract.
5. Hengstenberg C, Broeckel U, Holmer S, Glockner C, Mayer B, Commuzie AG, Riegger GAJ, Schunkert H. Genetic linkage analysis for C-reactive protein in families with myocardial infarction. Eur Heart J. 2003;24(suppl):156. Abstract.
6. Brull DJ, Serrano N, Zito F, Jones L, Montgomery HE, Rumley A, Sharma P, Lowe GDO, World MJ, Humphries SE, Hingorani AD. Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. 2003;23:2063-2069.
7. Goldman ND, Liu T, Lei K-J. Structural analysis of the locus containing the human C-reactive protein gene and its related pseudogene. J Biol Chem. 1987;262:7001-7005.
8. Kluft C. Is C-reactive protein an additional, surrogate end-point for statin treatment? Eur Heart J. 2002;23:761-764.
9. Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, Pepys MB. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med. 1999;190:1733-1740.
10. de Zwaan C, Kleine AH, Diris JH, Glatz JF, Wellens HJ, Strengers PF, Tissing M, Hack CE, van Dieijen-Visser MP, Hermens WT. Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur Heart J. 2002;23:1670-1677.
11. Cooper DN, Nussbaum RL, Krawczak M. Proposed guidelines for papers describing DNA polymorphism-disease associations. Hum Genet. 2002;110:207-208.
12. Wolford JK, Gruber JD, Ossowski VM, Vozarova B, Tataranni PA, Bogardus C, Hanson RL. A C-reactive protein promotor polymorphism is associated with type 2 diabetes mellitus in Pima Indians. Mol Genet Metab. 2003;78:136-144.
13. Zee RYL, Ridker PM. Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis. 2002;162:217-219.
14. Szalai AJ, McCrory MA, Cooper GS, Wu J, Kimberly RP. Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immun. 2002;3:14-19.
15. Wood WG, Ludemann J, Mitusch R, Heinrich J, Maass R, Frick U. Evaluation of a sensitive immunoluminometric assay for the determination of C-reactive protein (CRP) in serum and plasma and the establishment of reference ranges for different groups of subjects. Clin Lab. 2000;46:131-140.
16. Gussekloo J, Schaap MC, Frolich M, Blauw GJ, Westendorp RG. C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. Arterioscler Thromb Vasc Biol. 2000;20:1047-1051.
17. De Maat MPM, Kluft C. Determinants of C-reactive protein concentration in blood. Ital Heart J. 2001;2:189-195.
18. Liuzzo G, Buffon A, Biasucci LM, Gallimore JR, Caligiuri G, Vitelli A, Altamura S, Ciliberto G, Rebuzzi AG, Crea F, Pepys MB, Maseri A. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation. 1998;98:2370-2376.
19. Berger P, McConnell JP, Nunn M, Kornman KS, Sorrell J, Stephenson K, Duff GV. C-reactive protein levels are influenced by common IL-1 gene variation. Cytokine. 2002;17:171-174.
20. Ferrari SL, Ahn-Luong L, Garnero P, Humphries SE, Greenspan SL. Two promotor polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrin Metab. 2003;88:255-259.
21. Villuendas G, San Milan JL, Sancho J, Escobar-Morreale HF. The -597 G>A and -174 G>C polymorphisms in the promotor of the IL-6 gene are associated with hyperandrogenism. J Clin Endocrin Metab. 2002;87:1134-1141.
22. Kottmann T, Piper C, Farr M, Wiemer M, Baller D, Kleesiek K, Horstkotte D. The G allele of IL-6-174G/C polymorphism is a risk factor for restenosis after coronary stent implementation by increased inflammation and platelet activation. J Thromb Haemost. 2003;1(suppl):P0771. Abstract.
23. Brull DJ, Montgomery HE, Sanders J, Dhamrait S, Luong L, Rumley A, Lowe GDO, Humphries SE. Interleukin-6 gene -174 G>C and -572 G>C promotor polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol. 2001;21:1458-1463.
24. Burzotta F, Iacoviello L, Di Castelnuovo A, Glieca F, Luciani N, Zamparelli R, Schiavello R, Donati MB, Maseri A, Possati G, Andreotti F. Relation of the -174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization. Am J Cardiol. 2001;88:1125-1128.
25. Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem. 2000;275:18138-18144.
26. Kristiansen OP, Nolsoe RL, Larsen L, Gjesing AMP, Johannesen J, Larsen ZM, Lykkesfeldt AE, Karlsen AE, Pociot F, Mandrup-Poulsen T. Association of a functional 17beta-estradiol sensitive IL6-174G/C promotor polymorphism with early-onset type 1 diabetes in females. Human Mol Genet. 2003;12:1101-1110.
27. Wuyts B, Hetet G, Grandchamp B, Delanghe JR. Novel haptoglobin insertion/deletion polymorphism is associated with the lipid profile and C-reactive protein (CRP) concentration. Clin Chem Lab Med. 2002;40:469-474.
28. Braeckman L, De Bacquer D, Delanghe J, Claeys L, De Backer G. Associations between haptoglobin polymorphism, lipids, lipoproteins and inflammatory variables. Atherosclerosis. 1999;143:383-388.
29. Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE, Laurent GJ. Common promotor variant in cyclooxygenase-2 represses gene expression. Arterioscler Thromb Vasc Biol. 2002;22:1631-1636.
30. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, Willeit J, Schwartz DA. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med. 2002;347:185-192.
31. Hubacek JA, Stavek P, Pit'ha J, Skodova Z, Poledne R. CD14 (C-159 rarr; T) polymorphism and levels of C-reactive protein. Cas Lek Cesk. 2003;142:174-176.